This information is intended only for healthcare professionals resident in the United Kingdom


Prescribing Information (PI) for COMIRNATY LP.8.1® (mRNA encoding LP.8.1) COVID-19 mRNA vaccine and COMIRNATY XFG® (mRNA encoding XFG) COVID-19 mRNA vaccine for use in the private market

​​​​​

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via the Yellow card. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.

Alternatively, adverse events of concern in association with COMIRNATY can be reported to Pfizer Medical Information on 01304 616161 or via www.pfizersafetyreporting.com.

Please do not report the same adverse event(s) to both systems as all reports will be shared between Pfizer and MHRA (in an anonymised form) and dual reporting will create unnecessary duplicates.

Pfizer Ltd. accepts no responsibility for the content or services of the linked site other than the information relating to Pfizer medicines which it has provided or reviewed

United Kingdom

COMIRNATY KP.2 30 microgram/dose dispersion for injection in pre-filled syringe

COMIRNATY LP.8.1 (mRNA encoding LP.8.1) 30 microgram/dose dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine

COMIRNATY XFG (mRNA encoding XFG) 30 micrograms/dose dispersion for injection in pre-filled syringe COVID-19 mRNA Vaccine

PP-CMR-GBR-1102. September 2026